Clinical studies
[GIOTRIF] A sequential approach of first-line GIOTRIF® followed by various subsequent treatments can be a feasible and appropriate treatment option for patients with EGFR M+ NSCLC from TOAST study
[GIOTRIF] Over 1000 published cases of patients with uncommon EGFR M+ NSCLC treated with GIOTRIF®
[GIOTRIF] Based on current real-world and clinical trial evidences, the optimal regimen maybe first-line afatinib followed by osimertinib4-
